Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 4
Subjects
- Location of subjects
- Canada
- United States of America
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Cohort Cohort,cohort
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- PIDTC Cohort (CGD without IBD)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- NIHCC Cohort (CGD without IBD)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with Chronic granulomatous disease (CGD) without a history of Inflammatory bowel disease (IBD) and not receiving any medications other than prophylactic antimicrobials.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 23
- Group 1 sample size Number of subjects in the case (exposed) group
- 16
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- Recent treatment with nonprophylactic antibiotics (acute antibiotics)
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 2
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
- Chao1 Abundance-based estimator of species richness
- increased
Signature 1
Curated date: 2024/03/18
Curator: Ifyohondu
Revision editor(s): Ifyohondu, Folakunmi, ChiomaBlessing
Source: Fig. 3C
Description: Comparison of microbiome signatures between patients with CGD (without a history of IBD) from NIHCC VS PIDTC cohorts using LEfSe
Abundance in Group 1: decreased abundance in NIHCC Cohort (CGD without IBD)
| NCBI | Quality Control | Links |
|---|---|---|
| Enterococcus |
Revision editor(s): Ifyohondu, Folakunmi, ChiomaBlessing
Signature 2
Curated date: 2024/03/18
Curator: Ifyohondu
Revision editor(s): Ifyohondu, Folakunmi, ChiomaBlessing
Source: Fig. 3C
Description: Comparison of microbiome signatures between patients with CGD (without a history of IBD) from NIHCC VS PIDTC cohorts using LEfSe
Abundance in Group 1: increased abundance in NIHCC Cohort (CGD without IBD)
Revision editor(s): Ifyohondu, Folakunmi, ChiomaBlessing
